Legend Biotech Launches CAR-T Research Grant for Early-Career Clinicians

Legend Biotech has announced the launch of its inaugural ELITE Grant Program, an annual initiative designed to provide funding to early-career healthcare professionals conducting research, education, and innovation in multiple myeloma treatment, with a focus on CAR-T cell therapy.

The program targets a critical pipeline in oncology: the development of next-generation CAR-T approaches for multiple myeloma, a blood cancer that remains incurable for most patients despite recent therapeutic advances. By directing resources toward emerging researchers and clinicians, Legend Biotech aims to accelerate scientific progress at the stage where funding gaps are most acute.

Read more Al Mouj Muscat Business Park Nears Full Occupancy After Sellout →

The ELITE Grant Program reflects a broader industry trend of biopharmaceutical companies investing directly in physician-scientist pipelines. Early-career professionals often face the steepest barriers to securing competitive research funding, and targeted corporate grant programs have become one mechanism to bridge that gap, particularly in specialized therapeutic areas such as cell and gene therapy.

Legend Biotech, which co-developed the CAR-T therapy ciltacabtagene autoleucel with Johnson & Johnson for relapsed or refractory multiple myeloma, positions the program as part of its longer-term commitment to the disease area beyond its existing commercial portfolio. The annual cadence of the grant suggests sustained institutional investment rather than a one-time initiative.

No specific funding amounts, eligibility criteria, or application timelines were disclosed in the initial announcement. Continue reading at GlobeNewswire - Industry News on Financial Services.